2012 revenue: $10.16 billion
2011 revenue: $10.17 billion

Year in review: Roche's ($RHHBY) diagnostics division generated flat results, year over year, in a classic good news/bad news scenario. On the one hand, Roche's professional diagnostics unit grew a massive 10% in 2012, hitting $5.6 billion, and its molecular diagnostics business grew 7%, reaching the $1.3 billion mark as it accelerates development of drugs with companion diagnostics. But Roche's diabetes arm, including glucose monitors and blood glucose test development, dipped 3% to $2.8 billion in 2012, as European governments dropped reimbursement levels and global pricing pressures intensified. A restructuring, including layoffs and relocation of insulin pump R&D to Germany, is designed to help with a turnaround in 2013.

For more:
Roche Diagnostics leaps 4% in 2012, snags 20% market share
Roche Diagnostics cutting 100 jobs in diabetes restructuring